BACKGROUND: Cervical and endometrial carcinoma incidentally found in the surgical specimen with high risk pathological finding or with gross residual disease. MATERIAL AND METHODS: Between 2004 and 2010, 320 cervical and endometrial cancer patients were treated with EBRT and brachytherapy after having undergone total/subtotal hysterectomy. Sixty patients were lost to follow-up. RESULTS: Median follow-up was 21 months. Endometrial and cervical cancer with a high risk for local recurrence achieved CR 93.8 and 89 %, respectively. 56 % patients experienced CR with residual disease with cervical cancer. Median OS for endometrial and cervical cancer with residual disease was 8.5 and 24 months, respectively. Grade 3 adverse events were 5 and 3.5 % for rectum and bladder, respectively. CONCLUSION: The incorporation of chemotherapy during pelvic radiotherapy followed by HDR interstitial brachytherapy for residual disease is inadequate and improves survival. We are still in learning phase of brachytherapy in post-operative gynaecological malignancy cases; expertise will be developed by practice.
BACKGROUND: Cervical and endometrial carcinoma incidentally found in the surgical specimen with high risk pathological finding or with gross residual disease. MATERIAL AND METHODS: Between 2004 and 2010, 320 cervical and endometrial cancerpatients were treated with EBRT and brachytherapy after having undergone total/subtotal hysterectomy. Sixty patients were lost to follow-up. RESULTS: Median follow-up was 21 months. Endometrial and cervical cancer with a high risk for local recurrence achieved CR 93.8 and 89 %, respectively. 56 % patients experienced CR with residual disease with cervical cancer. Median OS for endometrial and cervical cancer with residual disease was 8.5 and 24 months, respectively. Grade 3 adverse events were 5 and 3.5 % for rectum and bladder, respectively. CONCLUSION: The incorporation of chemotherapy during pelvic radiotherapy followed by HDR interstitial brachytherapy for residual disease is inadequate and improves survival. We are still in learning phase of brachytherapy in post-operative gynaecological malignancy cases; expertise will be developed by practice.
Authors: Harriet O Smith; Clifford R Qualls; Audrey A Romero; Joel C Webb; Maxine H Dorin; Luis A Padilla; Charles R Key Journal: Gynecol Oncol Date: 2002-05 Impact factor: 5.482
Authors: Astrid N Scholten; Wim L J van Putten; Henk Beerman; Vincent T H B M Smit; Peter C M Koper; Marnix L M Lybeert; Jan J Jobsen; Carla C Wárlám-Rodenhuis; Karin A J De Winter; Ludy C H W Lutgens; Mat van Lent; Carien L Creutzberg Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-31 Impact factor: 7.038
Authors: K Hart; I Han; G Deppe; V Malviya; J Malone; C Christensen; P Chuba; A Porter Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-01 Impact factor: 7.038
Authors: Pooja K Nandwani; Rakesh K Vyas; J P Neema; Unnikrishan K Suryanarayan; Devang C Bhavsar; Kinjal R Jani Journal: J Cancer Res Ther Date: 2007 Apr-Jun Impact factor: 1.805
Authors: R A Sunil; Devang Bhavsar; M N Shruthi; U Suryanarayan Kunikullaya; R K Vyas; Ankita Parikh; Maitrik Jayantkumar Mehta; Pooja Nandwani Patel Journal: J Contemp Brachytherapy Date: 2018-04-30